ArticleThe oncologist2026

Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.

Xubiao Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.